Cat. #153163
Anti-S100A12 [NH4]
Cat. #: 153163
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: S100A12
Class: Polyclonal
Application: IHC ; IP ; WB
Reactivity: Human
Host: Rabbit
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Nancy Hogg
Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-S100A12 [NH4]
- Alternate name: MRP-6, calgranulin C, ENRAGE
- Research fields: Cell signaling and signal transduction;Immunology
- Clone: NH4
- Tool sub type: Primary antibody
- Class: Polyclonal
- Conjugation: Unconjugated
- Molecular weight: 6 kDa
- Reactivity: Human
- Host: Rabbit
- Application: IHC ; IP ; WB
- Description: Major biomarker of inflammation eg. inflammatory bowel disease, rheumatoid arthritis. Serves a ligand for RAGE (receptor for advanced glycation products) with role in tumour growth and wound healing.
- Immunogen: Recombinant human S100A12
- Recommended controls: Human neutrophils
Target Details
- Target: S100A12
- Molecular weight: 6 kDa
- Tissue cell line specificity: Human neutrophils
- Target background: Major biomarker of inflammation eg. inflammatory bowel disease, rheumatoid arthritis. Serves a ligand for RAGE (receptor for advanced glycation products) with role in tumour growth and wound healing.
Applications
- Application: IHC ; IP ; WB
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: Whole serum
- Storage conditions: -15° C to -25° C
- Shipping conditions: Dry ice
References
- Robinson et al. 2000. Biochem Biophys Res Commun. 275(3):865-70. PMID: 10973813.
- A comparison of human S100A12 with MRP-14 (S100A9).
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)
